Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Liabilities from Discontinued Operations (2018 - 2023)

Aclaris Therapeutics (ACRS) has 6 years of Liabilities from Discontinued Operations data on record, last reported at 2202000.0 in Q4 2023.

  • For Q4 2023, Liabilities from Discontinued Operations changed 0.0% year-over-year to 2202000.0; the TTM value through Dec 2023 reached 2202000.0, changed 0.0%, while the annual FY2023 figure was 2202000.0, 0.0% changed from the prior year.
  • Liabilities from Discontinued Operations reached 2202000.0 in Q4 2023 per ACRS's latest filing, roughly flat from 2202000.0 in the prior quarter.
  • Across five years, Liabilities from Discontinued Operations topped out at 4157000.0 in Q4 2019 and bottomed at 2198000.0 in Q3 2021.
  • Average Liabilities from Discontinued Operations over 5 years is 2610857.14, with a median of 2202000.0 recorded in 2021.
  • Peak YoY movement for Liabilities from Discontinued Operations: surged 238.79% in 2019, then plummeted 33.39% in 2021.
  • A 5-year view of Liabilities from Discontinued Operations shows it stood at 4157000.0 in 2019, then dropped by 25.16% to 3111000.0 in 2020, then decreased by 29.22% to 2202000.0 in 2021, then changed by 0.0% to 2202000.0 in 2022, then changed by 0.0% to 2202000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Liabilities from Discontinued Operations were 2202000.0 in Q4 2023, 2202000.0 in Q3 2023, and 2202000.0 in Q2 2023.